Compare Qurate Retail Inc Series A (QVCAQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Qurate Retail Inc Series A vs TG Therapeutics Inc — how do they compare? Qurate Retail Inc Series A trades at $0.04 (market cap $653.75K), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 12634.8× Qurate Retail Inc Series A's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Qurate Retail Inc Series A nearer its low. Which is the better fit depends on your goals.
| QVCAQ | TGTX | |
|---|---|---|
Market Cap | $653.75K | $8.26B |
Sector | Consumer Cyclical | Health |
52-Week High | $15.03 | $59.06 |
52-Week Low | $0.05 | $26.39 |
Enterprise Value | $4.73B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QVCAQ trades at $0.0515, down 12.12% in the past 24 hours, with a bearish technical signal from moving averages. The company reported a net loss of $2.44 billion in 2025 on revenue of $9.23 billion, with negative profit margins and declining revenue trends. Cash flow improved due to financing activities, but negative equity and high debt-to-asset ratios of 77.57% highlight financial stress. Recent news includes QVC celebrating 40 years of live shopping innovation with a TikTok Shop Super Brand Day (PRNewsWire, May 28, 2026).
The outlook remains challenging due to persistent losses, high leverage, and revenue declines. Investment opportunities are limited given weak fundamentals, though low P/E and P/B ratios may attract value hunters. Key risks include bankruptcy concerns from negative equity, competitive pressures in retail, and inability to achieve profitability. Analyst sentiment is cautious, with no bullish indicators supporting near-term recovery.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Qurate Retail Inc Series A
Qurate Retail Inc, through its subsidiaries, is engaged in the video and online commerce industries. Its segments include QxH, which includes QVC U.S. and HSN market and sell a wide variety of consumer products in the United States, primarily using their televised shopping programs and via the Internet through their websites and mobile applications
Read more on QVCAQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
